Morphosys Aktie News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Morphosys Aktie. Real-time updates on events, politics, business and more.

MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study Seite 1

December 11, 2023

11.12.2023 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve ... Seite 1

Raajitk Rampal Myeloproliferative Neoplasms Program Memorial Sloan Kettering Cancer Center Hematologic Malignancies Memorial Sloan Kettering Cancer

Source: wallstreet-online.de

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

November 21, 2023

20.11.2023 - Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)The key secondary endpoints assessing symptom reduction, ... Seite 1

Dynamic International Prognostic Scoring System Spleen Volume Morphosys Chart Orphosys Kurs Morphosys Aktie

Source: wallstreet-online.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Morphosys Aktie News Today

MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study Seite 1

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Explore More Categories